Literature DB >> 8573311

New tumor antigens recognized by T cells.

B Van den Eynde1, V G Brichard.   

Abstract

A series of tumor cell antigens that are recognized by cytolytic T lymphocytes has been characterized this year. Besides the antigens derived from proteins specifically expressed in tumors, many melanoma antigens derive from melanocytic differentiation proteins. In addition, antigens unique to individual tumors result from mutations in ubiquitously expressed genes.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8573311     DOI： 10.1016/0952-7915(95)80076-x

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  10 in total

Review 1.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

Review 2.  New therapeutic approaches based on gene transfer techniques.

Authors:  H Chong; R G Vile
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

4.  Transloading of tumor antigen-derived peptides into antigen-presenting cells.

Authors:  M Buschle; W Schmidt; W Zauner; K Mechtler; B Trska; H Kirlappos; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage.

Authors:  N Brouwenstijn; E H Slager; A B Bakker; M W Schreurs; C W Van der Spek; G J Adema; P I Schrier; C G Figdor
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 6.  Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic.

Authors:  Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2014-08       Impact factor: 11.151

7.  In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.

Authors:  S W Dow; R E Elmslie; A P Willson; L Roche; C Gorman; T A Potter
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

8.  Cell-free tumor antigen peptide-based cancer vaccines.

Authors:  W Schmidt; M Buschle; W Zauner; H Kirlappos; K Mechtler; B Trska; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

9.  A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

Authors:  S Mandruzzato; F Brasseur; G Andry; T Boon; P van der Bruggen
Journal:  J Exp Med       Date:  1997-08-29       Impact factor: 14.307

10.  BAP31, a promising target for the immunotherapy of malignant melanomas.

Authors:  Shaojuan Yu; Fuli Wang; Li Fan; Yuying Wei; Haitao Li; Yuanjie Sun; Angang Yang; Boquan Jin; Chaojun Song; Kun Yang
Journal:  J Exp Clin Cancer Res       Date:  2015-04-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.